Across TCGA pan-cancer cohorts, MYLIP Mutation is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MYLIP data layer compared with 22 for mass-spec protein.
The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher MYLIP Mutation is associated with better disease-free survival. In most high-consensus cancer types, elevated MYLIP expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.
UCEC, COAD, and LUSC are the cancer types where MYLIP Mutation most reproducibly stratifies survival.